Trial Profile

A Phase II Study of Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Sacituzumab govitecan (Primary)
Indications Adenocarcinoma; Bladder cancer; Carcinoma; Penile cancer; Renal cancer; Small cell lung cancer; Squamous cell cancer; Urogenital cancer
Focus Therapeutic Use
Acronyms SMART

02 Aug 2024 Planned initiation date (estimated date of first patient enrollement) changed from 31 Jul 2024 to 7 Aug 2024.
02 Aug 2024 Status changed from not yet recruiting to recruiting.
26 Jul 2024 Planned initiation date changed from 25 Jul 2024 to 31 Jul 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com